<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00727753</url>
  </required_header>
  <id_info>
    <org_study_id>EK-770</org_study_id>
    <nct_id>NCT00727753</nct_id>
  </id_info>
  <brief_title>VEGF-antagonism and Endothelial Function in Age-related Macular Degeneration (AMD)</brief_title>
  <official_title>Effects of Vascular Endothelial Growth Factor Antagonism With Ranibizumab or Bevacizumab in Patients With Neovascular Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the effects of 2 intravitreal injections with
      Ranibizumab or Avastin on endothelial function in subjects with neovascular macular
      degeneration compared to patients with dry AMD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change of endothelial function after 2 intravitreal injections and 8 weeks follow-up with ranibizumab or bevacizumab in patients with neovascular macular degeneration compared to patients with dry AMD.</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in cardiovascular and ophthalmological parameters.</measure>
    <time_frame>8 weeks</time_frame>
    <description>Secondary outcomes include evaluation of retinal thickness as measured by optical coherence tomography (OCT), change in best-corrected visual acuity (BCVA), &quot;Early Treatment Diabetic Retinopathy Study&quot; (ETDRS) letters, ambulatory blood pressure, vascular compliance, biomarkers of vascular function and platelet function.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">54</enrollment>
  <condition>Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Ranibizumab</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Bevacizumab</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Dry AMD</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>ranibizumab (0.5 mg) will be injected intraocular</description>
    <arm_group_label>Ranibizumab</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab (1.25 mg) will be injected intraocular</description>
    <arm_group_label>Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No treatment</intervention_name>
    <description>No treatment</description>
    <arm_group_label>Dry AMD</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        See eleigibility criteria
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for active treatment:

          -  Age: 50 - 80 years

          -  Diagnosis of neovascular macular degeneration suitable for intravitreal anti-VEGF
             therapy

          -  Stable medication for general conditions for at least 1 month

          -  Written informed consent for participation in the study

        Inclusion criteria for controls:

          -  Age: 50 - 80 years

          -  Diagnosis of &quot;dry&quot; AMD

          -  &quot;dry&quot; AMD is defined as at least Age-Related-Eye-Disease-Study (AREDS) category 2 in
             both eyes and no evidence of neovascularization in either eye

          -  Stable medication for general conditions for at least 1 month

          -  Written informed consent for participation in the study

        Exclusion Criteria for all subjects:

          -  Myocardial infarction, unstable angina, stroke within 3 months prior to study entry

          -  Thoracic or cardiac surgery and/or coronary intervention/revascularisation procedure
             (within 3 months before randomization)

          -  Uncontrolled symptomatic congestive heart failure (NHYA&gt; II) in the last 4 weeks prior
             to study

          -  Renal insufficiency (Creatinine Clearance &lt; 50ml/min)

          -  Ventricular tachyarrhythmias

          -  Poorly controlled hypertension, defined as resting blood pressure â‰¥ 160/100 mmHg

          -  Symptomatic hypotension

          -  Long acting nitrates

          -  Smoking (&gt;5 Zig./d)

          -  Diabetes mellitus

          -  Dyslipidemia (LDL-cholesterol &gt; 4.5 mmol/l)

          -  Liver disease (ALT or AST &gt;3x ULN)

          -  Alcohol or drug abuse

          -  Hypersensitivity to the active substance or to any of the excipients

          -  Active or suspected ocular or periocular infections

          -  Patients with active severe intraocular inflammation

          -  Malignancy (unless healed or remission &gt; 5 years)

          -  Disease with systemic inflammation (e.g. rheumatoid arthritis, M. Crohn)

          -  Participation in another study within the last month
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Ruschitzka, Prof MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Division of Cardiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Zurich, Division of Cardiology</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2008</study_first_submitted>
  <study_first_submitted_qc>August 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 4, 2008</study_first_posted>
  <last_update_submitted>May 27, 2015</last_update_submitted>
  <last_update_submitted_qc>May 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Macular Degeneration</keyword>
  <keyword>Age-Related Maculopathies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Endothelial Growth Factors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

